Kodak introduces new Vision3 products
ROCHESTER, N.Y. Kodak has added new products to its Vision3 line of motion picture products.
The stock additions include a medium-speed, tungsten-balanced color negative camera film and a color intermediate film optimized to work with digital post-production technologies.
“These new Vision3 films are the tangible result of our ongoing commitment to filmmakers,” said Kim Snyder, president of the Entertainment Imaging Division and VP of Eastman Kodak Co. “They were designed based on our customers’ suggestions and with the goal of increasing creative freedom and efficiencies in production and post-production. As filmmaking technology evolves, Kodak continues to lead the way, delivering the highest quality imaging systems and innovative products and services for visual storytellers,” Snyder added.
Crown Crafts acquires Bibsters product from P&G
GONZALES, La. Crown Crafts has acquired a disposable bib product from Procter & Gamble, the company announced last week.
Crown Crafts said its subsidiary Hamco now will manufacture and distribute Bibsters products, a disposable bib that provides coverage for infants and toddlers while feeding, which was introduced by P&G in 2003. Hamco also acquired the inventory associated with the Bibsters product line and plans to integrate the distribution of the Bibsters product line into the Company’s facilities in Compton, Calif.
“We are thrilled to find an opportunity that will complement last year’s acquisition of Neat Solutions by expanding our business in the disposable products category,” said E. Randall Chestnut, chairman, president and CEO. “Hamco already has the overwhelming market share in reusable bibs, and we are confident that the Bibsters line of disposable bibs will solidify Hamco’s position as the overall leader in infant and toddler bibs.”
FDA to review Orexigen’s obesity treatment
SAN DIEGO The Food and Drug Administration has accepted a new drug application from a biopharmaceutical company focused on the treatment of obesity.
Orexigen said its investigational obesity treatment Contrave (naltrexone SR/bupropion SR), which addresses both physiological and behavioral drivers of the disease, was accepted by the FDA, following its Contrave Obesity Research clinical program, which included more than 4,500 patients.
“We are pleased the FDA has accepted our NDA for filing and look forward to working with the agency during the review process,” said Michael Narachi, Orexigen president and CEO. “If approved, we believe Contrave will become an important therapeutic option for obese patients, making weight loss and weight maintenance an achievable cornerstone in the treatment of obesity and its common co-morbidities.”